← Ablatotech Vitals
Otolaryngology EvidenceDigest

Advancements in the Management of Sudden Idiopathic Sensorineural Hearing Loss

Otolaryngology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 7, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Idiopathic sudden sensorineural hearing loss (ISSNHL) remains a clinical emergency with evolving management strategies aiming to optimize hearing recovery. Systemic corticosteroids continue as first-line therapy, supported by robust guideline recommendations, while adjunctive treatments such as intratympanic steroids and hyperbaric oxygen therapy (HBOT) may benefit select patients. Emerging pathophysiologic phenotyping offers promise for precision medicine approaches. Safety considerations, particularly regarding corticosteroid adverse effects, are increasingly recognized. Despite advances, prognosis remains variable, underscoring the need for individualized treatment and further research (Chandrasekhar et al., 2019; Ibrahim et al., 2026; Wu et al., 2025).

Clinical bottom line

Idiopathic sudden sensorineural hearing loss (ISSNHL) remains a clinical emergency with evolving management strategies aiming to optimize hearing recovery. Systemic corticosteroids continue as first-line therapy, supported by robust guideline recommendations, while adjunctive treatments such as intratympanic steroids and hyperbaric oxygen therapy (HBOT) may benefit select patients. Emerging pathophysiologic phenotyping offers promise for precision medicine approaches. Safety considerations, particularly regarding corticosteroid adverse effects, are increasingly recognized. Despite advances, prognosis remains variable, underscoring the need for individualized treatment and further research (Chandrasekhar et al., 2019; Ibrahim et al., 2026; Wu et al., 2025).

What the evidence shows

The 2019 AAO-HNS Clinical Practice Guideline update by Chandrasekhar et al. remains the cornerstone reference, endorsing prompt initiation of systemic corticosteroids to improve hearing outcomes in ISSNHL. Intratympanic steroid injections are recommended as salvage therapy or primary treatment when systemic steroids are contraindicated.

Ibrahim et al. (2026) advance the concept of pathophysiologic phenotyping, identifying distinct ISSNHL subtypes based on vascular, inflammatory, or viral etiologies. This approach may guide tailored therapies in the future, though clinical application is still investigational.

Wu et al. (2025) provide a large clinical study on methylprednisolone sodium succinate, detailing adverse drug reactions and risk mitigation strategies, highlighting the importance of monitoring and patient selection to minimize corticosteroid-related complications.

Plaza et al. (2024) review systemic corticosteroid protocols, emphasizing dose, timing, and tapering regimens that balance efficacy and safety.

García Arumí et al. (2024) summarize evidence supporting HBOT as an adjunctive treatment, particularly when initiated early, noting improved hearing recovery rates in some cohorts.

Sahoo et al. (2014) and Seok et al. (2012) discuss alternative therapies such as acupuncture, though evidence remains limited and inconsistent.

Caveats and uncertainty

Heterogeneity in ISSNHL etiology and presentation complicates treatment standardization and prognostication.

High-quality randomized controlled trials comparing systemic versus intratympanic steroids, or evaluating combination therapies, are limited.

Optimal corticosteroid dosing and duration remain debated, with variable protocols reported.

HBOT availability and cost may restrict its use; evidence for its benefit is modest and best in early treatment windows.

Safety data on corticosteroids underscore the need for vigilance, especially in patients with comorbidities.

Emerging phenotyping approaches require validation before routine clinical implementation.

How this may change practice

Clinicians should continue to prioritize early systemic corticosteroid therapy, with intratympanic steroids as a valuable alternative or adjunct.

Incorporation of pathophysiologic phenotyping may eventually enable personalized treatment strategies, improving outcomes.

Enhanced awareness of corticosteroid adverse effects should prompt careful patient selection and monitoring.

HBOT may be considered in specialized centers for eligible patients, ideally within two weeks of symptom onset.

Multimodal treatment plans integrating pharmacologic and supportive therapies will likely evolve.

Ongoing research and guideline updates will refine management algorithms and prognostic tools.


References

  1. Chandrasekhar SS, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngol Head Neck Surg. 2019; DOI:10.1177/0194599819859885
  2. Chandrasekhar SS, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary. Otolaryngol Head Neck Surg. 2019; DOI:10.1177/0194599819859883
  3. Ibrahim I, et al. Pathophysiologic phenotyping of idiopathic sudden sensorineural hearing loss: toward precision management. Eur Arch Otorhinolaryngol. 2026; DOI:10.1007/s00405-026-10285-x
  4. Wu T, et al. Characteristics of adverse drug reactions and risk management strategies for methylprednisolone sodium succinate in the treatment of idiopathic sudden sensorineural hearing loss: a clinical study of 1026 patients. Front Med. 2025; DOI:10.3389/fmed.2025.1589531
  5. Plaza G, et al. Treatment of Idiopathic Sudden Sensorineural Hearing Loss with Systemic Corticosteroids. Sudden Sensorineural Hearing Loss. 2024; DOI:10.1007/978-3-031-61385-2_7
  6. García Arumí AM, et al. Treatment of Idiopathic Sudden Sensorineural Hearing Loss with Hyperbaric Oxygen Therapy. Sudden Sensorineural Hearing Loss. 2024; DOI:10.1007/978-3-031-61385-2_9
  7. Sahoo GC, et al. Idiopathic Sudden Sensorineural Hearing Loss. Emergencies in Otorhinolaryngology. 2014; DOI:10.5005/jp/books/12240_10
  8. Seok K, et al. Effects and Prognostic Factors of Acupuncture Treatment for Idiopathic Sudden Sensorineural Hearing Loss. Hearing Loss. 2012; DOI:10.5772/33340

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team